权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomedical Data Science Core

生物医学数据科学核心

基本信息

批准号：
10200772
负责人：
EDWARD E MORRISEY
金额：
$ 15.3万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10200772
关键词：
3-Dimensional Advocate Biological CRISPR/Cas technology Cell Culture Techniques Cell Line Cells Collaborations Core Facility Data Science Core Development Developmental Biology Digestive System Disorders Disease Ductal Epithelial Cell Endothelial Cells Ensure Epithelial Cells Esophagus Feedback Fibroblasts Fostering Future Gene Expression Gene-Modified Grant Hepatocyte Human Human Resources Infrastructure Institutes Instruction Intestines Leadership Liver Liver diseases Maintenance Mission Molecular Mus Mycoplasma Infections Names National Institute of Diabetes and Digestive and Kidney Diseases Nature Organoids Pancreas Pennsylvania Process Protocols documentation Quality Control RNA Interference Regenerative Medicine Reproducibility Research Services Standardization Structure of thyroid parafollicular cell System Techniques Technology Time Tissues Universities Viral Vector Vision bile duct biomedical data science cancer cell cost effective cost effective measures cost effectiveness embryonic stem cell established cell line experimental study in vivo induced pluripotent stem cell induced pluripotent stem cell technology member programs ranpirnase repository service member stem-like cell three dimensional cell culture tool translational medicine

项目摘要

PROJECT SUMMARY (CELL CULTURE AND iPS CORE) The Cell Culture and iPS Core (CCiC) facility is unique on the University of Pennsylvania campus and in the region. It serves a tremendous need by Center of Molecular Studies in Digestive and Liver Diseases (abbreviated as CMSDLD, which is the NIDDK P30 Digestive Diseases Research Core Center) members for services and technologies underlying Specific Aims related to primary cells and established cell lines, 3D culture systems (organotypic culture and organoids), manipulating gene expression in cell lines through RNA interference and CRISPR/Cas9, and the application of induced pluripotent stem cells (iPS) that have been genetically reprogrammed to an embryonic stem cell-like condition and differentiating such cells to discrete lineages (GI, pancreas, liver). Furthermore, the CCiC provides a rich repository of c cell lines (2D and 3D) that are well annotated for identity, passage and free of Mycoplasma infection thereby providing quality control, rigor and reproducibility. The CCiC provides standardized protocols and regular orientation and instruction, which prove to be cost-effective measures. There are emerging projects related to the use of iPS technology to correct disease states in enteroids and hepatocytes, remarkable illustrations of translational medicine fueled by the CCiC. Through its services, technologies, quality control and time/cost-effectiveness, the CCiC advances the CMSDLD's vision and missions on behalf of members/associate members/personnel.

项目总结（细胞培养和iPS核）